


## Troxeutin

<b>Cat. No.:</b>	HY-N0139
<b>CAS No.:</b>	7085-55-4
<b>Molecular Formula:</b>	C <sub>33</sub> H <sub>42</sub> O <sub>19</sub>
<b>Molecular Weight:</b>	742.68
<b>Target:</b>	NOD-like Receptor (NLR)
<b>Pathway:</b>	Immunology/Inflammation
<b>Storage:</b>	Powder    -20°C    3 years 4°C        2 years In solvent   -80°C    2 years -20°C    1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (134.65 mM; Need ultrasonic and warming)

H<sub>2</sub>O : ≥ 50 mg/mL (67.32 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.3465 mL	6.7324 mL	13.4647 mL
	5 mM	0.2693 mL	1.3465 mL	2.6930 mL
	10 mM	0.1346 mL	0.6732 mL	1.3465 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 0.5% CMC-Na/saline water  
Solubility: 24 mg/mL (32.32 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Troxeutin, also known as vitamin P4, is a tri-hydroxyethylated derivative of natural bioflavonoid rutins which can inhibit the production of reactive oxygen species (ROS) and depress ER stress-mediated NOD activation.

<b>IC<sub>50</sub> &amp; Target</b>	ROS <sup>[1]</sup> , NOD <sup>[2]</sup>
<b>In Vitro</b>	<p>The results reveal that the maximum protective effect against ROS induced cell damage in the HDP cells occurs following pretreatment with 10 μM Troxerutin. Treatment with H<sub>2</sub>O<sub>2</sub> alone decreases cell viability to 77.33±2.44%; however, pretreatment with 10 μM Troxerutin maintains cell viability at 90.88±2.24% following H<sub>2</sub>O<sub>2</sub> exposure (P&lt;0.05). At concentrations of 5 and 10 μM, pretreatment with Troxerutin causes a decrease in the number of cells in the sub G1 phase, indicative of cell death. In the control and Troxerutin-only-treated cells, 3.58±0.15 and 0.89±0.11% are 2'7'-dichlorofluorescein (DCF)-positive (P&lt;0.05), whereas treatment with H<sub>2</sub>O<sub>2</sub> alone increases the level of ROS to 46.36±2.33%. The cells pretreated with Troxerutin are 19.92±1.95% DCF-positive following H<sub>2</sub>O<sub>2</sub> treatment, indicating that Troxerutin reduces the H<sub>2</sub>O<sub>2</sub>-induced production of ROS in the HDP cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>Troxerutin effectively lowers body weight and obesity-related metabolic parameters in high-fat diet (HFD)-treated mice. Oral administration of Troxerutin notably inhibits those liver injuries in HFD-treated mice, restores glucose intolerance and insulin signaling, and diminishes hepatic gluconeogenesis in HFD-treated mice. Troxerutin remarkably inhibits the nuclear translocation of NF-κB p65, as well as the expressions of its target genes, in the livers of HFD-treated mice. Troxerutin also depresses endoplasmic reticulum (ER) stress-mediated Nucleotide oligomerization domain (NOD) activation in HFD-treated mouse livers<sup>[2]</sup>.</p> <p>Lipid depositions in tunica intima and tunica media are attenuated in Troxerutin-treated diabetic rats compare with untreated diabetic rats. Structural disarrangement and deformity of smooth muscle cells in aortic tissue of Troxerutin-treated diabetic rats are considerably lower than histology of untreated diabetic aorta. Administration of Troxerutin for four weeks to diabetic rats significantly reduces the level of malondialdehyde (MDA) compare to that of untreated diabetic rats (P&lt;0.01)<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## PROTOCOL

<b>Cell Assay</b> <sup>[1]</sup>	<p>The cells are plated at a density of 4×10<sup>3</sup>/well in a 96-well plate. At 70 to 80% confluence, the cells are treated with Troxerutin at concentrations ranging between 0 and 60 μM for 24 h at 37°C. Subsequently, 10 μL water soluble tetrazolium salt assay solution is added to each well and, following incubation for 30 min at 37°C, the optical density is measured at 490 nm using a reader. To examine Troxerutin mediated ROS protection, the cells are pretreated with Troxerutin at the following concentrations: 0, 5, 10 and 15 μM for 8 h. Subsequently, 750 μM H<sub>2</sub>O<sub>2</sub> is added to each well. Following incubation for 24 h at 37°C, cell viability is evaluated using an Cell Viability Assay kit. The level of cell viability (%) is normalized to that of 0.1% dimethyl-sulfoxide (DMSO)-treated cells. Each experiment is repeated at least three times<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>Animal Administration</b> <sup>[3]</sup>	<p>Thirty two adult male Wistar rats weighing 250 to 300 grams are used in this study. The animals are randomly divided into four groups (n=8/each) as: group I: control (C), group II: control with Troxerutin (C+TXR), group III: diabetic (D), and group IV: diabetic with Troxerutin (D+TXR). The control rats are received the same amount of citrate buffer alone. Development of diabetes is confirmed by measuring blood glucose levels, 72 hours later. Animals with blood glucose levels higher than 16.65 mM (300 mg/dL) are considered diabetic and those with blood glucose levels lower than this value are excluded from the experiment. Troxerutin (150 mg/kg/day) is administered orally, once daily for four weeks. After 10 weeks of induction of diabetes, diabetic animals as well as the time-matched controls are killed and aortic samples are collected<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## REFERENCES

[1]. Lim KM, et al. Analysis of changes in microRNA expression profiles in response to the troxerutin-mediated antioxidant effect in human dermal papilla cells. *Mol Med Rep.* 2015 Aug;12(2):2650-60.

[2]. Zhang Z, et al. Troxerutin Attenuates Enhancement of Hepatic Gluconeogenesis by Inhibiting NOD Activation-Mediated Inflammation in High-Fat Diet-Treated Mice. *Int*

---

J Mol Sci. 2016 Dec 25;18(1). pii: E31.

[3]. Badalzadeh R, et al. Beneficial effect of troxerutin on diabetes-induced vascular damages in rat aorta: histopathological alterations and antioxidation mechanism. Int J Endocrinol Metab. 2015 Apr 30;13(2):e25969.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA